DropsClinical Overview
Ofloxacin 0.3% w/v + Dexamethasone 0.1% w/v + Benzalkonium Chloride (As Preservative) 0.005% w/v Eye Drops is an evidence-based ophthalmic/otic formulation. It acts by delivering targeted active therapeutic substances to external ocular or auditory tissues to control infection, relieve inflammation, or restore tissue homeostasis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Instill prescribed drops into the conjunctival sac of the eye or auditory canal of the ear as directed by your physician under aseptic technique. Maintain dropper sterility.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Transient stinging, burning, local irritation. Rare/Severe: Hypersensitivity and localized epithelial toxicity.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
For external ophthalmic or otic use only. Discontinue if redness, swelling, or pain worsens. Keep dropper tip untouched.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or ophthalmic treatment recommendations. Always consult a registered ophthalmologist or ENT specialist before initiating, changing, or instilling any ophthalmic or otic medication.
Ofloxacin 200mg + Ornidazole 500mg Tablets
Ofloxacin and Ornidazole is a broad-spectrum fixed-dose antimicrobial combination pairing a fluoroquinolone with a nitroimidazole. Ofloxacin halts bacterial DNA multiplication, while ornidazole damages microbial DNA through free nitro radicals, eradicating anaerobes and protozoa. Indicated for mixed bacterial and protozoal gastroenteritis, amoebic dysentery, pelvic inflammatory disease, dental infections, and post-surgical abdominal sepsis.
Ofloxacin Tablets 200mg
Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.
Ofloxacin Tablets 400mg
Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.
Dexamethasone Tablets 0.5 mg
Dexamethasone (Tablets IP 0.5mg) is a long-acting synthetic fluorinated corticosteroid with 25 to 30 times the anti-inflammatory potency of hydrocortisone and virtually no mineralocorticoid (salt-retaining) activity, on the WHO Model List of Essential Medicines. It possesses exceptional tissue penetration including across the blood-brain barrier and placenta. Indicated for cerebral edema (brain tumors, trauma), severe COVID-19 with hypoxemia, croup, antenatal acceleration of fetal lung maturation in threatened preterm birth (24-34 weeks gestation), chemotherapy-induced nausea/vomiting, and severe allergic/anaphylactic crises.